Skip to main content
HEMOGENYX PHARMACEUTICALS PLC logo

HEMOGENYX PHARMACEUTICALS PLC — Investor Relations & Filings

Ticker · HEMO ISIN · GB00BYX3WZ24 LEI · 2138008L93GYU5GN6179 IL Manufacturing
Open in API
Filings indexed 473 across all filing types
Latest filing 2026-05-16 Annual Report
Country GB United Kingdom
Listing IL HEMO

About HEMOGENYX PHARMACEUTICALS PLC

https://hemogenyx.com/

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for life-threatening diseases. The company develops treatments for blood and autoimmune diseases, as well as viral infections. Its core technology includes advanced cell-based therapies, such as its proprietary Chimeric Antigen Receptor (CAR) T-cell platform, HEMO-CAR-T, which is being developed for the potential treatment of Acute Myeloid Leukemia (AML).

Recent filings

Filing Released Lang Actions
Group of companies' accounts made up to 2025-12-31
Annual Report Classification · 98% confidence The document is titled “Annual Report & Financial Statements for the Year Ended 31 December 2025” and contains the full set of annual report components: Chairman’s Statement, Strategic Report, Directors’ Report, Governance Report, Remuneration Report, Independent Auditor’s Report, complete financial statements (income statement, balance sheet, cash flows, statements of changes in equity), and notes. It is a comprehensive year-end report, not a brief announcement or presentation. This matches the definition of an Annual Report (Code: 10-K). FY 2025
2026-05-16 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'Annual Report & Financial Statements for the Year Ended 31 December 2025' and contains detailed sections typical of an annual report, including Chairman's Statement, Board of Directors, Governance Report, Directors' Remuneration Report, Independent Auditor's Report, and comprehensive financial statements such as Consolidated Statement of Comprehensive Income, Statement of Financial Position, Changes in Equity, Cash Flows, and Notes to the Financial Statements. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement. The content includes detailed financial and operational information for the full fiscal year 2025, consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-05-05 English
Final Results
Annual Report Classification · 95% confidence The document is titled 'Final Results' and announces the final audited results for the year ended 31 December 2025. It includes detailed financial and operational information, clinical progress, regulatory updates, capital raising activities, and outlook for the future. The text references the Annual Report being available on the company's website, but the document itself contains substantive financial and operational data, not just an announcement of the report's publication. The length of the document (15,000 characters) and the detailed content indicate this is the actual annual report or final results document rather than a brief announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K) covering the full financial performance and company activity for the fiscal year. FY 2025
2026-04-30 English
Institutional Fundraise
Capital/Financing Update Classification · 92% confidence The document is an RNS announcement disclosing that Hemogenyx Pharmaceuticals has secured £3 million through a direct subscription of new ordinary shares, provides details on the fundraising, Admission timing, and total voting rights. This clearly constitutes an update on the company’s financing activities. It is not a full report, AGM material, or earnings release, but a capital/financing update.
2026-04-28 English
Annual IND Report with FDA
Report Publication Announcement Classification · 82% confidence The document is an RNS press release announcing that Hemogenyx Pharmaceuticals has filed its Annual IND Report with the FDA; it is not the report itself but an announcement of its submission. This fits the “Report Publication Announcement” category rather than a substantive report (e.g., 10-K, IR) or any other specific filing. Hence, it should be classified as an RPA.
2026-04-14 English
Tech Transfer Completion and Clinical Trial Update
Regulatory Filings Classification · 85% confidence The document is an RNS release (Regulatory News Service) announcement providing an operational update on tech transfer completion and clinical trial progression for Hemogenyx Pharmaceuticals. It is not an earnings release, M&A, board change, or other specialized filing, but a general regulatory announcement under the UK Market Abuse Regulation. Therefore, it falls under the Regulatory Filings category.
2026-03-31 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.